NO2440239T3 - - Google Patents
Info
- Publication number
- NO2440239T3 NO2440239T3 NO10727289A NO10727289A NO2440239T3 NO 2440239 T3 NO2440239 T3 NO 2440239T3 NO 10727289 A NO10727289 A NO 10727289A NO 10727289 A NO10727289 A NO 10727289A NO 2440239 T3 NO2440239 T3 NO 2440239T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18554709P | 2009-06-09 | 2009-06-09 | |
| PCT/US2010/038046 WO2010144629A1 (en) | 2009-06-09 | 2010-06-09 | Hemoglobin compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2440239T3 true NO2440239T3 (US06362254-20020326-C00005.png) | 2018-02-10 |
Family
ID=42779888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO10727289A NO2440239T3 (US06362254-20020326-C00005.png) | 2009-06-09 | 2010-06-09 |
Country Status (31)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2440239T3 (US06362254-20020326-C00005.png) | 2009-06-09 | 2018-02-10 | ||
| US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| US10172949B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| US8609815B2 (en) * | 2010-09-02 | 2013-12-17 | Sangart, Inc. | Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant |
| BR112013017933B1 (pt) | 2011-01-14 | 2021-02-23 | Children's Hospital Los Angeles | composição líquida e métodos para sua fabricação |
| EP2550973B1 (en) * | 2011-07-23 | 2013-08-28 | SastoMed GmbH | Wound spray |
| JP6389125B2 (ja) * | 2011-11-07 | 2018-09-12 | ザ ジェネラル ホスピタル コーポレイション | 赤血球の処理法 |
| US10729748B2 (en) * | 2012-01-13 | 2020-08-04 | Mölnlycke Health Care Ab | Scarring reducing wound treatment |
| MX2014011186A (es) | 2012-03-20 | 2015-03-06 | Einstein Coll Med | Metodo para mejorar la eficiencia de las transfusiones de sangre. |
| US20150094267A1 (en) | 2012-04-03 | 2015-04-02 | Kim D. Vandegriff | Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins |
| US20140106004A1 (en) * | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| JP6657070B2 (ja) * | 2013-03-15 | 2020-03-04 | ウィリアム・シンドラーＷｉｌｌｉａｍ Ｓｃｈｉｎｄｌｅｒ | ポリアルキレンオキシド吉草酸ヘモグロビン接合体 |
| WO2014205077A1 (en) * | 2013-06-21 | 2014-12-24 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| CN103387613B (zh) * | 2013-08-02 | 2016-12-28 | 西北大学 | 一种血红蛋白及血红蛋白氧载体病毒灭活的方法 |
| CN103690978B (zh) * | 2013-12-19 | 2017-01-25 | 陕西佰美基因股份有限公司 | 一种用于血红蛋白及血红蛋白氧载体灭活病毒的方法 |
| US20170333566A1 (en) * | 2014-11-14 | 2017-11-23 | Aima Biotech | Conjugated Proteins |
| CN105749257B (zh) * | 2016-01-25 | 2019-12-06 | 四川大学华西医院 | 一种血红蛋白类携氧纳米凝胶及其制备方法和用途 |
| CN107007625A (zh) * | 2016-01-27 | 2017-08-04 | 上海本素医药科技有限公司 | 含一氧化碳的血液制剂及其在制备抗炎症药物中的应用 |
| CN109475511A (zh) * | 2016-05-19 | 2019-03-15 | 高等教育联邦系统-匹兹堡大学 | 还原态氧载体及其用于治疗碳氧血红蛋白血症的用途 |
| US10662063B1 (en) * | 2016-06-06 | 2020-05-26 | University Of Puerto Rico | Photosensitized release of nitric oxide |
| CN107625954A (zh) * | 2016-07-19 | 2018-01-26 | 上海本素医药科技有限公司 | 含一氧化碳的血红蛋白制剂及其在抗炎症中的应用 |
| MX2019013785A (es) * | 2017-05-19 | 2020-01-13 | New Health Sciences Inc | Metodos y tratamiento de trauma. |
| CN107952072B (zh) * | 2017-11-28 | 2021-07-20 | 深圳先进技术研究院 | 载药载氧杂交蛋白纳米粒的制备方法、载药载氧杂交蛋白纳米粒和应用 |
| EP3993778A2 (en) | 2019-07-02 | 2022-05-11 | HB02 Therapeutics, LLC | Hemoglobin substitute mixtures including reconstituted plasma and platelets and their manufacture and use |
| AU2021261405A1 (en) * | 2020-04-23 | 2022-11-10 | KaloCyte, Inc. | Self-assembling oxygen carrier compositions |
| EP4167961A4 (en) * | 2020-06-23 | 2024-03-13 | Virtech Bio, Inc. | COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC SHOCK |
| US20230398141A1 (en) * | 2020-09-08 | 2023-12-14 | The Brigham And Women's Hospital, Inc. | Therapeutic carbon monoxide formulations |
| US11857605B2 (en) | 2021-03-01 | 2024-01-02 | Billion King International Limited | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof |
| CN113813372A (zh) * | 2021-09-26 | 2021-12-21 | 云锦华彰(北京)生物科技有限公司 | 血红素组合物、药物组合物及其应用 |
| WO2023091642A1 (en) * | 2021-11-18 | 2023-05-25 | Virginia Commonwealth University | Modular field-stable bio-artificial blood substitute |
| CN113975378A (zh) * | 2021-11-19 | 2022-01-28 | 润方（北京）生物医药研究院有限公司 | 一种聚合血红蛋白在制备治疗缺血性脑卒中药物的应用 |
| WO2024081928A1 (en) * | 2022-10-14 | 2024-04-18 | Prolong Pharmaceuticals Llc | A stable hemoglobin protein composition |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3991181A (en) | 1975-06-18 | 1976-11-09 | Warner-Lambert Company | Injectable stroma free hemoglobin solution and its method of manufacture |
| US4401652A (en) | 1980-12-31 | 1983-08-30 | Allied Corporation | Process for the preparation of stroma-free hemoglobin solutions |
| JPS57206622A (en) | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
| DE3481109D1 (de) | 1983-05-09 | 1990-03-01 | Novo Nordisk As | Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren. |
| US5281579A (en) | 1984-03-23 | 1994-01-25 | Baxter International Inc. | Purified virus-free hemoglobin solutions and method for making same |
| US4831012A (en) | 1984-03-23 | 1989-05-16 | Baxter International Inc. | Purified hemoglobin solutions and method for making same |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| CA1312009C (en) | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Extra pure semi-synthetic blood substitute |
| US5084558A (en) | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
| GB8710598D0 (en) | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| WO1989009784A1 (en) | 1988-04-08 | 1989-10-19 | Commonwealth Serum Laboratories Commission | Production of heat-stable factor viii concentrate |
| US5428061A (en) | 1988-09-15 | 1995-06-27 | Schwarz Pharma Ag | Organic nitrates and method for their preparation |
| US5558985A (en) | 1989-03-27 | 1996-09-24 | Bionostics Incorporated | Stable hemoglobin reference solution |
| EP0470128B2 (en) | 1989-04-19 | 2003-08-13 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5342940A (en) | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
| US5284872A (en) | 1989-09-12 | 1994-02-08 | Schwarz Pharma Ag | Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof |
| US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5386014A (en) | 1989-11-22 | 1995-01-31 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute |
| US5478806A (en) | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
| US5312808A (en) | 1989-11-22 | 1994-05-17 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
| US5650388A (en) | 1989-11-22 | 1997-07-22 | Enzon, Inc. | Fractionated polyalkylene oxide-conjugated hemoglobin solutions |
| US5234903A (en) | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| EP0521873B1 (en) | 1990-01-29 | 1999-06-02 | Zymogenetics, Inc. | Anticoagulant proteins |
| US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| JP3459416B2 (ja) | 1991-02-28 | 2003-10-20 | ザイモジェネティクス，インコーポレイティド | 修飾されたファクター▲ｖｉｉ▼ |
| US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5376524A (en) | 1991-04-01 | 1994-12-27 | Thomas Jefferson University | Platelet storage medium containing acetate and phosphate |
| DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| EP0676964B1 (en) | 1991-11-14 | 2001-01-24 | Brigham And Women's Hospital | Nitrosylation of enzyme sh groups as a therapeutic modality |
| IT1260468B (it) | 1992-01-29 | 1996-04-09 | Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole | |
| AU670793B2 (en) | 1992-04-30 | 1996-08-01 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor VIII complex |
| US5264555A (en) | 1992-07-14 | 1993-11-23 | Enzon, Inc. | Process for hemoglobin extraction and purification |
| WO1994004193A1 (en) | 1992-08-21 | 1994-03-03 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| US5650447A (en) | 1992-08-24 | 1997-07-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitric oxide-releasing polymers to treat restenosis and related disorders |
| KR100303872B1 (ko) | 1992-10-02 | 2001-11-22 | 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 | 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법 |
| AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
| US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
| US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
| SE9301581D0 (sv) | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
| DE4321306A1 (de) | 1993-06-26 | 1995-01-05 | Sanol Arznei Schwarz Gmbh | Disulfide |
| US5407579A (en) | 1993-07-02 | 1995-04-18 | National Science Council | Hemoglobin purification |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5691452A (en) | 1995-03-23 | 1997-11-25 | Biopure Corporation | Method for preserving a hemoglobin blood substitute |
| US6271351B1 (en) | 1995-03-23 | 2001-08-07 | Biopure Corporation | Method for preserving a hemoglobin blood substitute |
| US5703073A (en) | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| US5585484A (en) | 1995-04-19 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Hemoglobin crosslinkers |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5932538A (en) | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| US6310052B1 (en) | 1996-06-04 | 2001-10-30 | Queen's University At Kingston | Nitrate esters and their use for neurological conditions |
| US5807847A (en) | 1996-06-04 | 1998-09-15 | Queen's University At Kingston | Nitrate esters |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| US5849314A (en) | 1996-06-28 | 1998-12-15 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Anhydrous cosmetic compositions |
| US5808011A (en) | 1996-07-01 | 1998-09-15 | Biopure Corporation | Method for chromatographic removal of prions |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| CA2270118A1 (en) | 1996-11-01 | 1998-05-14 | Nitromed Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| US6054427A (en) * | 1997-02-28 | 2000-04-25 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
| US6232336B1 (en) | 1997-07-03 | 2001-05-15 | The United States Of America As Represented By The Department Of Health And Human Services | Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same |
| ZA988662B (en) | 1997-10-10 | 1999-03-31 | Baxter Int | Storage-stable hemoglobin compositions |
| US6656452B1 (en) | 1997-10-21 | 2003-12-02 | The General Hospital Corporation | Use of inhaled NO as anti-inflammatory agent |
| US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| CA2316834C (en) | 1998-01-07 | 2006-01-03 | Shearwater Polymers, Inc. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
| PT1061954E (pt) | 1998-03-12 | 2004-10-29 | Nektar Therapeutics Al Corp | Derivados de poli(etileno glicol) com grupos reactivos proximos |
| DE19838481C1 (de) | 1998-08-25 | 2000-03-23 | Michael T Witt | Anlage zur solarthermischen Energiegewinnung |
| US6773613B1 (en) | 1998-10-15 | 2004-08-10 | Sangart, Inc. | Method for production of stroma-free hemoglobin |
| WO2000028065A1 (en) | 1998-11-06 | 2000-05-18 | Novo Nordisk A/S | Method for the production of fvii |
| US6437102B1 (en) | 1999-11-24 | 2002-08-20 | Bayer Corporation | Method of separating prions from biological materials |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6376604B2 (en) | 1999-12-22 | 2002-04-23 | Shearwater Corporation | Method for the preparation of 1-benzotriazolylcarbonate esters of poly(ethylene glycol) |
| DE60138364D1 (de) | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| EP1282693B1 (en) | 2000-05-03 | 2010-10-20 | Novo Nordisk Health Care AG | Human coagulation factor vii variants |
| KR100396983B1 (ko) | 2000-07-29 | 2003-09-02 | 이강춘 | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 |
| IL154520A0 (en) | 2000-09-13 | 2003-09-17 | Novo Nordisk As | Human coagulation factor vii variants |
| US7173000B2 (en) | 2000-11-09 | 2007-02-06 | The Scripps Research Institute | Modified factor VIIa |
| JP2005501060A (ja) | 2001-08-10 | 2005-01-13 | ニトロメッド，インク． | 硫黄含有有機硝酸化合物の使用法 |
| US6649072B2 (en) | 2001-11-16 | 2003-11-18 | Robert Brandt | Method for producing autologous platelet-rich plasma |
| US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US20050164915A1 (en) | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US7001715B2 (en) | 2002-02-28 | 2006-02-21 | Biopure Corporation | Purification of red blood cells by separation and diafiltration |
| DE10212321A1 (de) | 2002-03-20 | 2003-10-09 | Sanguibio Tech Ag | Verwendung eines oder mehrerer von Plasma und Zellwandbestandteilen befreiten natürlichen oder modifizierten Sauerstoffbinder zur externen Behandlung offener, insbesondere chronischer Wunden |
| US7144989B2 (en) | 2002-03-25 | 2006-12-05 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof |
| US6901941B2 (en) * | 2002-07-10 | 2005-06-07 | Air Products And Chemicals, Inc. | Vessel with optimized purge gas flow and method using same |
| US20040072729A1 (en) * | 2002-10-10 | 2004-04-15 | Sunbio Inc. | High oxygen affinity PEG-hemoglobin as treatment for brain stroke |
| WO2004043381A2 (en) | 2002-11-08 | 2004-05-27 | The Brigham And Women's Hospital, Inc. | Compositions and methods for prolonging survival of platelets |
| AU2003299700B2 (en) | 2002-12-23 | 2009-03-26 | Albert Einstein College Of Medicine Of Yeshiva University | Modified hemoglobin and methods of making same |
| ES2347805T3 (es) | 2004-08-31 | 2010-11-04 | Sangart, Inc. | Metodos para aumentar la estabilidad hemodinamica usando composiciones que transportan oxigeno. |
| CA2600927C (en) * | 2005-03-07 | 2017-04-18 | Sangart, Inc. | Compositions and methods for delivering carbon monoxide (co) and nitric oxide (no) to tissue using heme proteins as carriers |
| JP4665791B2 (ja) | 2005-04-15 | 2011-04-06 | ニプロ株式会社 | 酸素運搬体の脱一酸化炭素化方法、脱一酸化炭素化された酸素運搬体、その医薬組成物及び脱一酸化炭素化装置 |
| WO2006135740A1 (en) | 2005-06-10 | 2006-12-21 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated hemoglobin and albumin and uses thereof |
| JP5020525B2 (ja) | 2006-03-30 | 2012-09-05 | 財団法人生産開発科学研究所 | 配位子置換型輸液製剤 |
| US7759306B2 (en) | 2006-05-16 | 2010-07-20 | Simoni Jan S | Methods of treating acute blood loss |
| JP2008195656A (ja) | 2007-02-14 | 2008-08-28 | Nipro Corp | 人工酸素運搬体製剤 |
| NO2440239T3 (US06362254-20020326-C00005.png) | 2009-06-09 | 2018-02-10 | ||
| US7932356B1 (en) | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
-
2010
- 2010-06-09 NO NO10727289A patent/NO2440239T3/no unknown
- 2010-06-09 US US12/797,582 patent/US10080782B2/en active Active
- 2010-06-09 DK DK17188857.1T patent/DK3266463T3/da active
- 2010-06-09 ME MEP-2017-237A patent/ME02979B/me unknown
- 2010-06-09 EP EP17188857.1A patent/EP3266463B1/en active Active
- 2010-06-09 CN CN201080025493.4A patent/CN102458451B/zh active Active
- 2010-06-09 MY MYPI2017000063A patent/MY192541A/en unknown
- 2010-06-09 KR KR1020187033506A patent/KR20180126103A/ko not_active Application Discontinuation
- 2010-06-09 PT PT107272890T patent/PT2440239T/pt unknown
- 2010-06-09 CA CA2764872A patent/CA2764872C/en active Active
- 2010-06-09 JP JP2012515116A patent/JP6227870B2/ja active Active
- 2010-06-09 LT LTEP10727289.0T patent/LT2440239T/lt unknown
- 2010-06-09 RS RS20171004A patent/RS56496B1/sr unknown
- 2010-06-09 SI SI201031546T patent/SI2440239T1/en unknown
- 2010-06-09 WO PCT/US2010/038046 patent/WO2010144629A1/en active Application Filing
- 2010-06-09 ES ES10727289.0T patent/ES2643462T3/es active Active
- 2010-06-09 AU AU2010258752A patent/AU2010258752B2/en active Active
- 2010-06-09 AR ARP100102035A patent/AR077041A1/es unknown
- 2010-06-09 BR BRPI1010775A patent/BRPI1010775A2/pt not_active IP Right Cessation
- 2010-06-09 KR KR1020187037893A patent/KR102210133B1/ko active IP Right Grant
- 2010-06-09 NZ NZ597022A patent/NZ597022A/en not_active IP Right Cessation
- 2010-06-09 DK DK10727289.0T patent/DK2440239T3/en active
- 2010-06-09 EP EP10727289.0A patent/EP2440239B1/en active Active
- 2010-06-09 KR KR1020127000555A patent/KR20120052221A/ko active Application Filing
- 2010-06-09 RU RU2011153748/15A patent/RU2589254C2/ru not_active IP Right Cessation
- 2010-06-09 TW TW099118756A patent/TWI626057B/zh not_active IP Right Cessation
- 2010-06-09 PL PL10727289T patent/PL2440239T3/pl unknown
- 2010-06-09 PL PL17188857.1T patent/PL3266463T3/pl unknown
- 2010-06-09 ES ES17188857T patent/ES2966234T3/es active Active
- 2010-06-09 MX MX2011013215A patent/MX342787B/es active IP Right Grant
- 2010-06-09 KR KR1020177022846A patent/KR102170375B1/ko active IP Right Grant
- 2010-06-09 HU HUE10727289A patent/HUE037163T2/hu unknown
- 2010-06-09 MY MYPI2011005954A patent/MY184447A/en unknown
-
2011
- 2011-11-17 IL IL216404A patent/IL216404A/en not_active IP Right Cessation
- 2011-12-06 CL CL2011003091A patent/CL2011003091A1/es unknown
- 2011-12-13 ZA ZA2011/09176A patent/ZA201109176B/en unknown
-
2015
- 2015-10-07 AU AU2015238812A patent/AU2015238812B2/en active Active
- 2015-11-30 JP JP2015232933A patent/JP6377036B2/ja active Active
-
2016
- 2016-11-22 US US15/358,447 patent/US10780148B2/en active Active
-
2017
- 2017-02-24 AU AU2017201272A patent/AU2017201272B2/en active Active
- 2017-07-27 JP JP2017145738A patent/JP6483766B2/ja active Active
- 2017-10-04 HR HRP20171480TT patent/HRP20171480T1/hr unknown
- 2017-10-05 CY CY20171101036T patent/CY1119578T1/el unknown
-
2018
- 2018-02-24 HK HK18102671.2A patent/HK1243628A1/zh unknown
- 2018-06-28 AU AU2018204708A patent/AU2018204708B2/en active Active
- 2018-08-22 US US16/109,239 patent/US10772937B2/en active Active
